 |
4 Diseases |  |
1 Trial |
|
1 Trial |  |
4 News |  |
- ||||||| Catioprost (latanoprost emulsion) / Santen
Trial completion: A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan (clinicaltrials.gov) - May 28, 2024
P3, N=386, Completed, Sponsor: Santen SAS
Active, not recruiting --> Completed
- | latanoprost / Generic mfg.
Journal: New trends towards glaucoma treatment: Topical osmoprotective microemulsions loaded with latanoprost. (Pubmed Central) - Jun 10, 2023
Relative ocular bioavailability was 4.5 and 19 times higher than the marketed formulation. These findings suggest the use of these microemulsions as potential combined strategies for extended surface protection and glaucoma treatment.
- ||||| Catioprost (latanoprost emulsion) / Santen
Enrollment closed, Trial completion date, Trial primary completion date: A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan (clinicaltrials.gov) - May 26, 2022
P3, N=386, Active, not recruiting, Sponsor: Santen SAS
These findings suggest the use of these microemulsions as potential combined strategies for extended surface protection and glaucoma treatment. Recruiting --> Active, not recruiting | Trial completion date: Apr 2021 --> Oct 2022 | Trial primary completion date: Dec 2020 --> Feb 2022
- | latanoprost / Generic mfg.
Journal: A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study. (Pubmed Central) - May 6, 2022
The new latanoprost nanoemulsion is significantly less cytotoxic on human conjunctival cells than LSc. These results suggest that the new formulation might be gentler on the eye surface than currently available BAK-preserved latanoprost solutions.
- Catioprost (latanoprost emulsion) / Santen
Interactions in vitro and in vivo of Catioprost with human meibum and Tear Films (Room 316) - Mar 9, 2020 - Abstract #ARVO2020ARVO_1806;
Similar effects on TFLL and TF were observed in vivo at the ocular surface. In vitro and in vivo data complement each other and facilitated the study of the composition-structure-function relationship that determines the impact of cationic nanoemulsions on TF.
- | Catioprost (latanoprost emulsion) / Santen
New P3 trial: A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan (clinicaltrials.gov) - Oct 20, 2019
P3, N=380, Recruiting, Sponsor: Santen SAS
- |||| Catioprost (latanoprost emulsion) / Santen
Trial completion: Safety and Efficacy Study of Catioprost (clinicaltrials.gov) - May 12, 2013
P2, N=105, Completed, Sponsor: Novagali Pharma
In vitro and in vivo data complement each other and facilitated the study of the composition-structure-function relationship that determines the impact of cationic nanoemulsions on TF. Active, not recruiting --> Completed